Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
Public ClinicalTrials.gov record NCT01794182. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multi-Center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, multi-center, prospective, double blind study. The primary objective is to assess the efficacy and safety of glyburide (RP-1127) compared to placebo in participants with a severe anterior circulation ischemic stroke who are likely to develop malignant edema.This objective will be addressed by comparing the proportion of glyburide treated particpants and placebo treated participants with a Day 90 modified Rankin Scale (mRS) ≤ 4 without decompressive craniectomy (DC). The secondary objective is to assess the efficacy of RP-1127 compared to placebo in participants with a severe anterior circulation ischemic stroke who were likely to develop malignant edema.
Study identification
- NCT ID
- NCT01794182
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 86 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 12, 2013
- Primary completion
- Apr 3, 2016
- Completion
- Apr 3, 2016
- Last update posted
- Nov 11, 2024
2013 – 2016
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Medical Center | Tucson | Arizona | 85719 | — |
| Stanford University Medical Center | Stanford | California | 94305 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06510 | — |
| University of Florida, Jacksonville | Jacksonville | Florida | 32209 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | — |
| University of Louisville Hospital | Louisville | Kentucky | 40202 | — |
| Maine Medical Center | Scarborough | Maine | 04074 | — |
| University of Maryland School of Medicine | Baltimore | Maryland | 21201 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| UMASS Memorial Medical Center | Worcester | Massachusetts | 01655 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | — |
| Oregon Health & Science University Hospital | Portland | Oregon | 97239 | — |
| Abington Memorial Hospital | Abington | Pennsylvania | 19001 | — |
| UPMC Presbyterian Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| University of Utah Healthcare | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01794182, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 11, 2024 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01794182 live on ClinicalTrials.gov.